



Glaukos Announces the Release of its 2025 Sustainability Report

2026-04-16

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that it has published its 2025 Sustainability Report. The report highlights the company's continued commitment and progress on its key corporate sustainability priorities. The Sustainability Report can be found on the company's website [here](#).

"I am proud to issue our seventh annual Sustainability Report, which highlights the meaningful progress we continue to make in advancing our core corporate sustainability initiatives that are aligned with our mission and key strategic plans," said Thomas Burns, Glaukos chairman and chief executive officer. "Innovation is at the core of everything we do, and it informs not only our product strategy, but also how we approach sustainability, governance, and our responsibilities as a global healthcare leader. We believe the programs, policies, and achievements detailed in this report provide compelling examples of our dedication to sustainability, an important pillar of both our culture and brand."

Throughout 2025, Glaukos continued to advance its corporate sustainability strategy, achieving several key milestones, including:

- Provided more than \$22 million in product donations to date, helping expand access to essential vision care in underserved regions globally.
- Logged approximately 870 employee volunteer hours across 61 community service events, with an additional 321 families supported during the holiday season.
- Launched an updated Code of Conduct and associated employee training programs and online tools, reinforcing a strong culture of ethics and compliance across the organization.
- Achieved 100% company-wide completion of annual cybersecurity awareness training.
- Broke ground on a new R&D and manufacturing facility in Huntsville, Alabama, supporting long-term innovation and operational growth.
- Received FDA approval for Epioxa™ and advanced preparations for 2026 commercial launch, alongside expanded patient awareness and support initiatives.
- Collaborated with patient advocacy organizations to conduct awareness-building outreach, educating nearly 15,000 glaucoma and keratoconus patients.
- Reached approximately 14,000 keratoconus patients served since the inception of Glaukos Patient Services.
- Launched the Glaukos Culture Leaders program, focused on strengthening employee engagement and fostering a high-performance culture.
- Completed a climate risk assessment aligned with Task Force on Climate-Related Financial

- Disclosures (TCFD) recommendations.
- Received external limited assurance of greenhouse gas (GHG) emissions calculations and disclosures, enhancing transparency and accountability.
- Increased 401(k) company match, enhancing employee financial wellness benefits.
- Achieved strong participation in the company's Employee Stock Purchase Plan (ESPP).

For additional information and highlights, please see Glaukos' 2025 Sustainability Report, which can be found on the company's website [here](#).

Glaukos' sustainability initiatives are overseen by the company's board of directors.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for *iDose*[®] TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, our ability to achieve the sustainability goals and targets identified in the sustainability report. Historical, current and forward-looking sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future. The information included in, and any issues identified as material for purposes of this document may not be considered material for Securities and Exchange Commission (SEC) reporting purposes. In the context of this disclosure, the term "material" is distinct from, and should not be confused with, such term as defined for SEC reporting purposes. These and other risks, uncertainties and factors related to Glaukos, and our business are described in detail under the caption "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 23, 2026. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or

otherwise, except as may be required under applicable securities law.

Media Contact:

Silvana Guerci-Lena

(508) 808-8993

GlaukosMedia@powers-co.com

Investor Contact:

Chris Lewis

Vice President, Investor Relations & Corporate Affairs

clewis@glaukos.com

Source: Glaukos Corporation